Evidence map›Paper›PMID 41572319›Full record

ArticleChinese medicine2026

Mangiferin inhibits cGAS-STING pathway-related inflammation via Nrf2 activation to protect against sepsis-induced heart injury.

Junna Song, Meng Wang, Qian Li, Wanting Zhao, Xiangming Chen, Chunhua Li, Qingmei Guo

Abstract read
In one paragraph

Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Mitochondrial DNA as a driver of inflammation via the cGAS-STING pathway.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junna Song *School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Meng Wang *College of Life Science, Hebei Normal University, Shijiazhuang, Hebei, China.
Qian Li *College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Wanting ZhaoCollege of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Xiangming ChenCollege of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Chunhua LiCollege of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Qingmei GuoSchool of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. qingmeiguo2024@163.com.

Funding

National Natural Science Foundation of China 81803762Natural Science Foundation of Shandong Province, China ZR2021MH123Supporting Plan for 100 Excellent Innovative Talents in Colleges and Universities of Hebei Province (III) SLRC2019044Talent Training Funding Project of Hebei Province A201901037the Natural Science Foundation of Hebei Province H2022423317
6 · The paper itself

Abstract

backgroundSeptic cardiomyopathy is characterized by oxidative stress and inflammation, and accounts for its associated high mortality. Mangiferin is a naturally occurring xanthonoid found abundantly in Anemarrhena asphodeloides Bunge, a traditional Chinese herb widely used for treatment of cardiovascular diseases. This study was designed to investigate the cardioprotective role of mangiferin against sepsis-induced heart injury with a focus on mitochondrial DNA (mtDNA) release and cGAS-STING pathway-related inflammation.

methodsThe septic cardiomyopathy model in mice was established by intraperitoneal injection of LPS (10 mg/kg). Cardiac Nrf2 in septic mice was knocked down with AAV9-CTNT-Nrf2 shRNA to confirm the activity of mangiferin. Cardiomyocytes were cultured with LPS for further in vitro studies.

resultsOral administration of mangiferin enhanced the survival of mice against endotoxin-induced insult. When LPS challenge impaired cardiac structural integrity, mangiferin reduced macrophage recruitment in the heart and inhibited the gene expression of pro-inflammatory cytokines. In the septic heart, mangiferin increased Nrf2 protein expression, thereby protecting the heart from oxidative damage. Mechanistically, mangiferin increased Nrf2 protein abundance by promoting Keap-1 degradation, which in turn prevented Nrf2 from undergoing proteasomal degradation. Unlike nuclear DNA (nDNA), mitochondrial DNA (mtDNA) acts as a ligand to induce toll-like receptor (TLR) activation once released into the cytoplasm. By protecting mitochondrial membrane integrity, mangiferin combated oxidative stress to prevent mitochondrial fragmentation and prevented the opening of mitochondrial permeability transition pore (mPTP) and the collapse of mitochondrial membrane potential in a manner this is dependent on Nrf2 availability. These effects were, however, blocked in the presence of a special Nrf2 inhibitor, ML385. Similar to TLR4, TLR9 is a member of the damage-associated molecular patterns (DAMPs). It can induce immune response through STING/IRF3 signaling. In septic mouse heart, mangiferin inhibited cGAS activity, deactivated STING/IRF3 signaling via dephosphorylation and resultantly suppressed interferon response due to limited mtDNA leakage. In cultured cardiomyocytes, mangiferin blocked STING/IRF3 signaling cascades in a Nrf2-dependent manner. Cardiac knockdown of Nrf2 with AAV9-CTNT-Nrf2 shRNA in septic mice demonstrated that Nrf2 deficiency diminished the inhibitory effects of mangiferin on cGAS-STING pathway-related inflammation.

conclusionThrough Nrf2 activation, mangiferin ameliorates mitochondrial dysfunction to block mtDNA release and subsequent cGAS-STING pathway-related inflammation, resultantly protecting the heart against septic insult. These events suggest the potential in the treatment of heart injury from the perspective of mitochondrial protection.

Indexed as

CGAS-STING pathwayHeart sepsisMangiferinMtDNANrf2

Identifiers

PMID41572319
PMCPMC12829080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.